CRIS Current Research Information System

PARISI, SARAH
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.226
NA - Nord America 7.049
EU - Europa 5.780
AF - Africa 571
SA - Sud America 381
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 18
Totale 21.044
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.932
CN - Cina 1.945
SG - Singapore 1.887
VN - Vietnam 1.835
GB - Regno Unito 1.513
SE - Svezia 977
IT - Italia 872
DE - Germania 709
HK - Hong Kong 404
FR - Francia 339
IN - India 338
RU - Federazione Russa 274
BR - Brasile 256
KR - Corea 203
IE - Irlanda 196
NL - Olanda 193
JP - Giappone 166
ZA - Sudafrica 154
TG - Togo 115
FI - Finlandia 108
CI - Costa d'Avorio 100
UA - Ucraina 93
NG - Nigeria 90
GR - Grecia 89
SC - Seychelles 86
EE - Estonia 85
CA - Canada 73
CH - Svizzera 70
JO - Giordania 68
BD - Bangladesh 64
AR - Argentina 58
BG - Bulgaria 57
PH - Filippine 47
BE - Belgio 37
TR - Turchia 36
TH - Thailandia 33
IR - Iran 31
ES - Italia 29
AT - Austria 27
MX - Messico 27
PL - Polonia 27
IQ - Iraq 25
ID - Indonesia 24
PK - Pakistan 20
EU - Europa 18
TW - Taiwan 17
UZ - Uzbekistan 17
EC - Ecuador 16
AU - Australia 14
RO - Romania 14
HR - Croazia 12
LT - Lituania 11
SA - Arabia Saudita 11
CO - Colombia 10
PY - Paraguay 10
LB - Libano 9
MY - Malesia 9
VE - Venezuela 9
CZ - Repubblica Ceca 8
PE - Perù 8
CL - Cile 7
PT - Portogallo 7
IL - Israele 6
MA - Marocco 6
MK - Macedonia 6
OM - Oman 6
EG - Egitto 5
KZ - Kazakistan 5
AE - Emirati Arabi Uniti 4
JM - Giamaica 4
NZ - Nuova Zelanda 4
RS - Serbia 4
UY - Uruguay 4
AL - Albania 3
AZ - Azerbaigian 3
ET - Etiopia 3
HU - Ungheria 3
KE - Kenya 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
BA - Bosnia-Erzegovina 2
CY - Cipro 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
HN - Honduras 2
KG - Kirghizistan 2
KH - Cambogia 2
LV - Lettonia 2
SI - Slovenia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
DM - Dominica 1
GA - Gabon 1
GE - Georgia 1
GY - Guiana 1
KW - Kuwait 1
Totale 21.026
Salva come PNG Salva come JPEG
Città #
Southend 1.379
Singapore 1.316
Ashburn 792
Chandler 630
Fairfield 502
San Jose 424
Hefei 415
Hong Kong 387
Dong Ket 368
Ho Chi Minh City 323
Ann Arbor 299
Houston 296
Beijing 290
Hanoi 289
Wilmington 285
Woodbridge 259
Santa Clara 248
Princeton 233
Seattle 225
Bologna 198
Dublin 193
Boardman 188
Cambridge 182
Seoul 158
Tokyo 122
Lauterbourg 119
Westminster 117
Lomé 115
Nanjing 114
New York 112
Padova 104
Abidjan 100
Medford 84
Helsinki 82
Los Angeles 79
Amman 67
Frankfurt am Main 65
Milan 65
Jinan 63
Bern 61
Abeokuta 57
Dallas 57
Sofia 56
Munich 54
Berlin 53
Haiphong 53
Redwood City 50
Shenyang 50
Buffalo 48
Redondo Beach 47
Saint Petersburg 44
Bremen 42
Nanchang 42
São Paulo 42
Da Nang 41
Hebei 40
Johannesburg 40
Bengaluru 37
Turin 37
Brussels 36
Florence 35
Tianjin 35
Changsha 34
Council Bluffs 32
Shanghai 31
Orem 29
Rome 27
San Diego 27
Zhengzhou 27
Jiaxing 26
Guangzhou 25
Grafing 23
Chicago 22
Falls Church 22
Jacksonville 21
Toronto 21
Paris 20
Turku 20
Falkenstein 19
London 19
Biên Hòa 18
Istanbul 17
Nuremberg 17
Phoenix 17
Tongling 17
Vienna 17
Amsterdam 16
Atlanta 16
Wuhan 16
Chengdu 15
Hyderabad 15
Norwalk 15
Athens 14
Hải Dương 14
Mountain View 14
Redmond 14
Baghdad 13
Bangkok 13
Brooklyn 13
Davao City 13
Totale 13.093
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 355
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 324
Clinical and molecular insights in erythropoiesis regulation of signal transduction pathways in myelodysplastic syndromes and β-thalassemia 291
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 282
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 267
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 267
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes 263
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 260
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 254
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 254
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 249
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 244
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 237
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 235
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 234
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 232
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 230
Large cell non Hodgkin’s lymphoma: what is new in the WHO classification? 228
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 228
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 228
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 228
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes 227
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 223
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 223
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients 220
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 219
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 219
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 217
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 217
Immunosenescence and immunotherapy in elderly acute myeloid leukemia patients: Time for a biology-driven approach 216
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 215
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 213
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF IS FREQUENTLY DELETED BUT NOT MUTATED IN BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 213
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 212
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 210
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 208
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 207
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 206
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 204
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 203
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 202
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 200
Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells 199
The more, the better: "Do the right thing" for natural killer immunotherapy in acute myeloid leukemia 198
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 196
Signaling pathways and bone marrow microenvironment in myelodysplastic neoplasms 193
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 192
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 191
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 191
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 190
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 189
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 188
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 186
The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. 186
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 183
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 181
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 178
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 177
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 177
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 176
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 175
EFFICACY AND FEASIBILITY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): A SINGLE-CENTER EXPERIENCE 175
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 173
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 173
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 172
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 172
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 169
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 169
SNP array reveals a new deletion of JAK2 in AML patients 169
A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination 165
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 163
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 163
GENETIC VARIATIONS IN ADH1A AND CYP2E1 STRONGLY AFFECTS RESPONSE AND TOXICITY TO A COMBINATION OF GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS 161
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 160
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 160
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 159
COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES 157
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 156
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 155
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin 154
MULTIPLEX PCR TO RAPIDLY IDENTIFY IKZF1 (IKAROS) GENE BREAKPOINTS IN BCRABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 152
Indoleamine 2,3-Dioxygenase (IDO) Is Associated with High Incidence of Chemorefractory Disease in Acute Myeloid Leukemia (AML) Patients 152
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 152
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 152
DEREGULATED EXPRESSION OF CHECKPOINT KINASE 1 (CHK1) IN BCR-ABL-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (BCR-ABL+ ALL) SUGGESTS A NEW THERAPEUTIC TARGET 151
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 150
Pediatric-Like Intensified Therapy In Adult Acute Lymphoblastic Leukemia: A Single Centre Experience 149
LOSS OF CDKN2A GENE IS A POOR PROGNOSTIC MARKER IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS 148
Nelarabine front-line therapy for adult T-Lymphoblastic leukaemia/Lymphoma (T-LBL/ALL): preliminary results of a single centre experience 143
SEVERAL FUSION TRANSCRIPTS ARE DETECTED BY NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING APPROACH IN ADULT BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 141
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 141
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 137
Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) 136
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 134
The role of the loss of CDKN2A gene on prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia (ALL) 132
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 132
FLUDARABINE, CYTARABINE, IDARUBICIN AND ETOPOSIDE (FLAIE) SCHEDULE IS SAFE AND ACTIVE FOR YOUNG PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS OF A MULTICENTRIC PHASE III ITALIAN STUDY 131
A phase I study of Tipifarnib and Bortezomib in the treatment of poor risk adult acute myeloid leukemia (AML) 130
Patient with ataxia telangiectasia who developed acute myeloid leukemia. 129
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 129
Totale 19.356
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.360
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.360
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021731 0 0 0 0 0 0 0 0 0 0 0 731
2021/20222.503 225 55 166 278 254 136 54 162 126 182 436 429
2022/20232.804 312 451 121 357 233 233 93 177 438 53 192 144
2023/2024781 37 111 37 92 64 170 40 40 44 55 55 36
2024/20252.785 126 416 228 195 322 105 244 101 27 260 183 578
2025/20266.759 627 722 548 492 713 313 638 281 1.507 552 210 156
Totale 21.422